Combination therapy with cyclosporine in rheumatoid arthritis

The role of combination therapy in rheumatoid arthritis is increasing with the recent development of various new treatment modalities. While past combinations of slow acting antirheumatic drugs have resulted in either excessive side effects or lack of efficacy over single agent therapy, recent combinations appear more promising. Recently, the combination of cyclosporine and methotrexate (MTX) was shown to be more efficacious than MTX alone. Improved methodology and a better understanding of the mechanisms of action of these newer agents is responsible for these exciting results.